Compare TG Therapeutics Inc (TGTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Materials Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Materials Select Sector SPDR Fund trades at $51.45. Which is the better fit depends on your goals.
| TGTX | XLB | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | — |
52-Week High | $59.06 | $53.67 |
52-Week Low | $26.94 | $42.23 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The ETF offers broad exposure to the materials sector, which is benefiting from infrastructure spending and AI-related demand. Recent news highlights the sector's potential for earnings growth and defensive characteristics in the current market environment.
The materials sector appears well-positioned for continued growth with strong Q2 earnings momentum and AI infrastructure tailwinds. However, investors face risks from cyclical sector exposure and potential geopolitical supply chain disruptions. Current technical strength suggests near-term upside potential, though valuation metrics remain unavailable for detailed fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
